These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 15479485

  • 1. Future directions with angiogenesis inhibitors in colorectal cancer.
    Bilenker JH, Haller DG.
    Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S86-93. PubMed ID: 15479485
    [Abstract] [Full Text] [Related]

  • 2. Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer.
    Penland SK, Goldberg RM.
    Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S74-80. PubMed ID: 15479483
    [Abstract] [Full Text] [Related]

  • 3. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
    Los M, Roodhart JM, Voest EE.
    Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
    [Abstract] [Full Text] [Related]

  • 4. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
    Venook AP.
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
    [No Abstract] [Full Text] [Related]

  • 5. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S.
    Cochrane Database Syst Rev; 2009 Jul 08; (3):CD005392. PubMed ID: 19588372
    [Abstract] [Full Text] [Related]

  • 6. Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
    Kabbinavar FF, Ellis LM.
    Clin Colorectal Cancer; 2004 Oct 08; 4 Suppl 2():S69-73. PubMed ID: 15479482
    [Abstract] [Full Text] [Related]

  • 7. Future directions in the use of antiangiogenic agents in patients with colorectal cancer.
    Hoff PM.
    Semin Oncol; 2004 Dec 08; 31(6 Suppl 17):17-21. PubMed ID: 15696026
    [Abstract] [Full Text] [Related]

  • 8. American Society of Clinical Oncology-39th Annual Meeting. Angiogenesis. 31 May-3 June 2003, Chicago, IL, USA.
    Erlich R, Durrance A.
    IDrugs; 2003 Jul 08; 6(7):623-4. PubMed ID: 12906003
    [No Abstract] [Full Text] [Related]

  • 9. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
    Heinemann V, Hoff PM.
    Oncology; 2010 Jul 08; 79(1-2):118-28. PubMed ID: 21088438
    [Abstract] [Full Text] [Related]

  • 10. Antiangiogenic therapy of colorectal cancer: state of the art, challenges and new approaches.
    Sarmiento R, Longo R, Gasparini G.
    Int J Biol Markers; 2012 Dec 27; 27(4):e286-94. PubMed ID: 23280126
    [Abstract] [Full Text] [Related]

  • 11. Antiangiogenic therapy: more promise and, yet again, more questions.
    Ellis LM.
    J Clin Oncol; 2003 Nov 01; 21(21):3897-9. PubMed ID: 14517185
    [No Abstract] [Full Text] [Related]

  • 12. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.
    Hurwitz H.
    Clin Colorectal Cancer; 2004 Oct 01; 4 Suppl 2():S62-8. PubMed ID: 15479481
    [Abstract] [Full Text] [Related]

  • 13. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
    Jackson C, Cunningham D.
    Eur J Cancer; 2008 Mar 01; 44(5):652-62. PubMed ID: 18313913
    [Abstract] [Full Text] [Related]

  • 14. [Anti-angiogenic treatment and colorectal cancer].
    André T, Tournigand C, Abbas F, Louvet C, de Gramont A, Gercor (French Oncology Research Group).
    Bull Cancer; 2007 Jul 01; 94 Spec No():S211-9. PubMed ID: 17846007
    [Abstract] [Full Text] [Related]

  • 15. Update on angiogenesis inhibitors.
    Zakarija A, Soff G.
    Curr Opin Oncol; 2005 Nov 01; 17(6):578-83. PubMed ID: 16224236
    [Abstract] [Full Text] [Related]

  • 16. Challenges and pitfalls of combining targeted agents in phase I studies.
    Cannistra SA.
    J Clin Oncol; 2008 Aug 01; 26(22):3665-7. PubMed ID: 18669449
    [No Abstract] [Full Text] [Related]

  • 17. Bevacizumab: improved survival at what cost?
    Kolesar JM.
    Am J Health Syst Pharm; 2005 May 15; 62(10):1017. PubMed ID: 15901584
    [No Abstract] [Full Text] [Related]

  • 18. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy.
    Blagosklonny MV.
    Cancer Biol Ther; 2005 Dec 15; 4(12):1307-10. PubMed ID: 16322683
    [Abstract] [Full Text] [Related]

  • 19. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?
    Montagnani F, Migali C, Fiorentini G.
    J Clin Oncol; 2009 Oct 01; 27(28):e132-3; author reply e134-5. PubMed ID: 19720898
    [No Abstract] [Full Text] [Related]

  • 20. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH, Jensen BV, Larsen FO.
    Acta Oncol; 2010 Apr 01; 49(3):395-6. PubMed ID: 20001495
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.